STERIS plc

(New York Stock Exchange)
Back to all articles
Bullish +75

STERIS Q4 Earnings Call Highlights

AI-generated analysis

πŸ“ˆ STERIS reported record fiscal 2026 revenue of approximately $6 billion, driven by mid- to high-single-digit growth despite a lighter fourth quarter.

πŸ’° Fourth-quarter revenue grew 7% as reported, with constant currency organic revenue increasing 5% due to volume and pricing gains.

πŸ“‰ Gross margin decreased 30 basis points to 44%, while EBIT margin reached 24.2%, the highest for fiscal 2026 but down from the prior year due to inflation and tariffs.

πŸ’΅ Adjusted net income was $278.3 million with diluted earnings per share of $2.83, up 3% year-over-year despite higher tax rates limiting growth.

πŸ“Š CEO Dan Carestio highlighted a 10% rise in adjusted earnings per share to $10.17 for fiscal 2026, even as tariffs reduced margins by 80 basis points.

πŸ’§ Free cash flow for fiscal 2026 totaled $982.9 million, supported by higher earnings and capital expenditures of $369 million.

🏦 The company ended the year with $1.9 billion in total debt and a gross debt-to-EBITDA ratio of about 1.2 times, below its target range.

πŸ₯ Healthcare segment revenue grew 9% as reported, led by 12% growth in service revenue and a capital equipment backlog just under $400 million.

πŸ§ͺ Applied Sterilization Technologies (AST) grew 10% as reported but faced softer results due to U.S. snowstorms and cautious MedTech inventory management.

πŸ”¬ Life Sciences segment grew 9% with significant capital equipment growth of 15% as customers resumed investment after a prior downturn.

πŸ“… For fiscal 2027, STERIS expects revenue growth of 7% to 8% and adjusted earnings per share between $11.10 and $11.30.

⚠️ Management adopted a conservative view on AST for fiscal 2027 due to difficult comparisons and ongoing inventory reductions in the MedTech sector.

πŸ“‰ Tariff spending is expected to remain flat at $60 million to $65 million in fiscal 2027, with no tariff refunds included in guidance.

πŸ’° The quarterly dividend increased by $0.06 to $0.63, marking the 20th consecutive year of dividend growth for the company.

πŸ”„ STERIS approved a new $1 billion share buyback authorization and plans annual repurchases between $200 million and $300 million.

🀝 Two tuck-in acquisitions in Healthcare are expected to contribute about $45 million in combined revenue starting in fiscal 2027.

🏭 The company plans to build a new sterility assurance manufacturing plant in Mentor, Ohio, intended to consolidate U.S. production.

πŸ”§ The new Ohio facility is projected to cost about $60 million over two years and become operational by the end of calendar 2027.

πŸ“ˆ Capital expenditures for fiscal 2027 are planned at $375 million, with priorities shifting toward automation and capacity expansion.

🌍 STERIS operates as a global provider of infection prevention and contamination control products for healthcare, life sciences, and pharmaceutical industries.

Bullish Signals
  • STERIS reported record annual revenue for fiscal 2026, with total company revenue reaching approximately $6 billion.
  • Adjusted earnings per rose 10% to $10.17, demonstrating strong profitability despite margin pressures from tariffs.
  • The Healthcare segment grew 9% as reported and generated $4 billion in revenue and $1 billion in operating income for the year.
  • Capital equipment backlog in the Healthcare segment reached just under $400 million, with orders up 2% in the fourth quarter.
  • Life Sciences exceeded $250 million in operating profit for the first time, driven by a 15% increase in capital equipment growth as customers resumed investment.
  • Fiscal 2027 outlook includes mid- to high-single-digit organic revenue growth and expected EBIT margin expansion of approximately 50 basis points.
  • Adjusted earnings per share are expected to grow 9% to 11% in fiscal 2027, with targets set between $11.10 and $11.30.
  • The company increased its quarterly dividend by $0.06 to $0.63, marking its 20th consecutive year of dividend growth.
  • STERIS announced a new $1 billion share buyback authorization and plans consistent annual buybacks in the range of $200 million to $300 million.
  • The company completed two tuck-in acquisitions expected to contribute about $45 million of combined revenue in fiscal 2027.
Risk Factors
  • Adjusted net income growth was limited in the fourth quarter due to a lower gross margin and a higher effective tax rate of 25.4%, up from 23.5% the prior year.
  • The Applied Sterilization Technologies segment delivered results lighter than expected, citing second-half softness and severe U.S. snowstorms early in the calendar year that impacted fourth-quarter services revenue.
  • Management is taking a more conservative view on AST growth for fiscal 2027 due to MedTech customers carefully managing inventory levels and difficult first-half comparisons.
  • The company noted some inventory reduction across the broader MedTech customer segment, which could constrain near-term demand visibility despite underlying procedure rates remaining resilient.
  • Fiscal 2027 guidance assumes a flat tariff spending range of $60 million to $65 million with no inclusion of potential tariff refunds, creating downside risk if trade policy shifts.
Full Analysis
STERIS (NYSE: STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue of approximately $6 billion and resilient procedure demand. Fourth-quarter revenue grew 7% as reported, while constant currency organic revenue increased 5%, driven by volume and pricing gains that offset higher tariffs and inflation. Adjusted net income from continuing operations was $278.3 million, with adjusted diluted earnings per share rising 3% to $2.83. Fiscal 2026 adjusted earnings per rose 10% to $10.17, even as tariffs reduced margins by 80 basis points. Free cash flow for fiscal 2026 was $982.9 million, and the company ended the year with $1.9 billion in total debt and a gross debt-to-EBITDA ratio of about 1.2 times. Segment performance was led by Healthcare growth, which increased 9% as reported and 8% on a constant currency organic basis, generating $4 billion in revenue and $1 billion in operating income for the year. The Applied Sterilization Technologies segment grew 10% as reported, though results were lighter than expected due to second-half softness and severe U.S. snowstorms early in the calendar year. Life Sciences grew 9% as reported, benefiting from a 15% increase in capital equipment growth as customers resumed investment after a prior downturn. The company expects fiscal 2027 as-reported revenue growth of 7% to 8%, with constant currency organic revenue growth of 6% to 7%. Fiscal 2027 adjusted earnings per share are expected to be $11.10 to $11.30, representing 9% to 11% growth over fiscal 2026. Capital allocation includes a quarterly dividend increase to $0.63, $225 million in share repurchases, and a new $1 billion buyback authorization. The company completed two tuck-in acquisitions in Healthcare expected to contribute about $45 million of combined revenue in fiscal 2027. STERIS plans fiscal 2027 capital expenditures of $375 million and free cash flow of $850 million. A new sterility assurance manufacturing plant is planned for Mentor, Ohio, intended to consolidate existing U.S. production into a state-of-the-art facility with an expected investment of about $60 million over two years.